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Background: Several bone implants are applied in clinical practice, but none meets the requirements of an ideal
implant. Platelet-rich plasma (PRP) is an easy and inexpensive way to obtain growth factors in physiologic proportions
that might favour the regenerative process. The aim of this review is to analyse clinical studies in order to investigate
the role of PRP in favouring bone integration of graft, graft substitutes, or implants, and to identify the materials for
which the additional use of PRP might be associated with superior osseo- and soft tissues integration.
Methods: A search on PubMed database was performed considering the literature from 2000 to 2012, using the
following string: ("Bone Substitutes"[Mesh] OR "Bone Transplantation"[Mesh] OR "Bone Regeneration"[Mesh] OR
"Osseointegration"[Mesh]) AND ("Blood Platelets"[Mesh] OR "Platelet-Rich Plasma"[Mesh]). After abstracts screening, the
full-texts of selected papers were analyzed and the papers found from the reference lists were also considered. The
search focused on clinical applications documented in studies in the English language: levels of evidence included in
the literature analysis were I, II and III.
Results: Literature analysis showed 83 papers that fulfilled the inclusion criteria: 26 randomized controlled trials (RCT),
14 comparative studies, 29 case series, and 14 case reports. Several implant materials were identified: 24 papers on
autologous bone, 6 on freeze-dried bone allograft (FDBA), 16 on bovine porous bone mineral (BPBM), 9 on β-tricalcium
phosphate (β-TCP), 4 on hydroxyapatite (HA), 2 on titanium (Ti), 1 on natural coral, 1 on collagen sponge, 1 on medical-
grade calcium sulphate hemihydrate (MGCSH), 1 on bioactive glass (BG) and 18 on a combination of biomaterials. Only
4 papers were related to the orthopaedic field, whereas the majority belonged to clinical applications in oral/maxillofacial
surgery.
Conclusions: The systematic research showed a growing interest in this approach for bone implant integration, with an
increasing number of studies published over time. However, knowledge on this topic is still preliminary, with the
presence mainly of low quality studies. Many aspects still have to be understood, such as the biomaterials that can
benefit most from PRP and the best protocol for PRP both for production and application.
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Osseointegration is achieved when there is no progressive
relative movement between the implant and the bone in
direct contact with it [1], and is the result of two complex
stages: osteoinduction, the process by which osteogenesis
is induced and osteoconduction, the growth of bone on a
surface [2]. Osteoinduction is a part of the normal bone
healing process and is responsible for the majority of* Correspondence: e.kon@biomec.ior.it
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reproduction in any medium, provided the ornewly formed bone. Osteoconduction also occurs during
normal remodelling in bone and depends not only on bio-
logical factors, but also on the response to a foreign
material [2].
Several bone substitutes materials are currently being
applied in clinical practice [3], but none meets all the re-
quirements of an ideal implant. Ideally, to obtain good
osseointegration, bone implants should provide four ele-
ments: structural integrity; an osteoconductive matrix as a
scaffold that permits bone ingrowth; osteogenic cells,
which offer the potential to differentiate and facilitate the
various stages of bone regeneration; and osteoinductived. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bone regeneration and repair [3].
Growth factors (GFs) are expressed during different
phases of tissue healing and are therefore a key element
in promoting tissue regeneration [4]; in fact, GFs carried
on orthopaedic devices have been reported to enhance
osteoblastic activity and favour implant integration [5,6].
Platelet-rich plasma (PRP) is an inexpensive way to ob-
tain many GFs in physiological proportion and has
already been largely applied as a carrier of GFs in differ-
ent fields of medicine (sports medicine, orthopaedics,
dermatology, ophthalmology, plastic and maxillofacial
surgery, neurosurgery, urology, and cardiothoracic sur-
gery…) due to its property of favouring tissue healing
even in tissues with low healing potential [7-10].
PRP can be defined as a blood derivate where platelets
have a higher concentration above baseline levels. In
clinical practice PRP has been applied in musculoskel-
etal treatment, with results reported on cartilage, bone,
muscle, tendon and ligament regeneration, and also as
an augmentation procedure to favour implant healing,
although this aspect has not been largely documented
in the literature [7,9]. The first evidence of the clinical
benefits of PRP in implant osseointegration was re-
ported in 1998 by Marx et al. [11], who studied 88 pa-
tients with mandibular defects treated with platelet
concentrate and cancellous cellular marrow bone graft.
Results showed that PRP allowed a radiographic graft mat-
uration rate of 1.62 to 2.16 times higher than that without
PRP at six months, and also showed greater bone density.Figure 1 Flow diagram of the systematic review process.Since then the use of PRP has been broadened as an aug-
mentation procedure for several applications.
The aim of this review is to analyse all the existing
published clinical studies in order to investigate the role
of PRP in favouring integration of bone-graft, bone-graft
substitutes, or bone-implants with bone and/or soft tis-
sues, and to identify the materials for which the add-
itional use of PRP might be associated with superior
osseo- and soft tissues integration.
Methods
A search was performed on the PubMed database
considering the literature from 2000 to 2012, using the
following string: ("Bone Substitutes"[Mesh] OR "Bone
Transplantation"[Mesh] OR "Bone Regeneration"[Mesh]
OR "Osseointegration"[Mesh]) AND ("Blood Platelets"
[Mesh] OR "Platelet-Rich Plasma"[Mesh]). After abstracts
screening, the full-texts of selected papers were analyzed
and the papers found from the reference lists were also
considered for the literature analysis of this review
(Figure 1).
The search focused on clinical applications docu-
mented in studies in the English language: the levels of
evidence for the literature analysis were I to III.
Papers were classified according to the level of evi-
dence and biomaterial in order to understand the poten-
tial of PRP to favour the osseointegration of different
types of biomaterials. In particular, RCTs have been ana-
lysed in the text and summarized in Table 1, whereas
comparative trials were synthesize in Table 2. Only
Table 1 Published results on PRP clinical application to favor bone implant integration (R: randomized trial; C:
comparative study; +: results in favor of PRP; -: no benefit from PRP; +/−: doubtful results on PRP usefullness for bone
scaffold integration)
Publication N° pts Study
type





Khairy NM [12] 15 R + BPBM Camargo PM [13] 28 C +/−
J Oral Maxillofac Surg - 2012 Int J Per Rest Dent - 2005
Wei LC [14] 276 R + Hanna R [15] 13 R +/−
J Orthop Res - 2012 J Periodontol - 2004
Sys J [16] 40 R – Lekovic V [17] 52 C +/−
Eur Spine J - 2011 J Clin Periodontol - 2003
Luaces-Rey R [18] 20 C – Camargo PM [19] 18 C +/−
Med Oral Patol Oral
Cir Bucal - 2010
J Periodontal Res - 2002
Badr M [20] 21 R – β-TCP Ozdemir B [21] 14 R –
Eur J Oral Implantol - 2010 J Biomed Mater Res B - 2012
Bettega G [22] 18 C + Saini N [23] 20 C +
Transfusion - 2009 Indian J Dent Res - 2011
Lee C [24] 30 C + Harnack L [25] 22 R –
Int J Oral Maxillofac Surg - 2009 Clin Oral Investig - 2009
Schaaf H [26] 34 R – Dori F [27] 28 R –
Oral Surg Radiol Endod - 2008 J Periodontol - 2008
Consolo U [28] 16 R + Yassibag-Berkman Z [29] 25 R –
Clin Oral Impl Res - 2006 J Periodontol - 2007
Raghoebar GM [30] 30 R – Wiltfang J [31] 39 R +
Clin Oral Implants Res - 2005 Clin Oral Implants Res - 2003
FDBA Markou N [32] 24 R – HA Menzes LM [33] 60 R +
J Periodontol - 2009 Quitessence Int - 2012
Piemontese M [34] 60 R – Vaishnavi C [35] 20 R +
J Periodontol - 2008 J Conserv Dent - 2011
Kassolis JD [36] 10 R + Okuda K [37] 35 R +/−
J Craniofac Surg - 2005 J Periodontol - 2005
BPBM Anitua E [38] 5 C + BG Demir B [39] 29 R –
Clin Impl Dent Rel Res - 2012 J Clin Periodontol - 2007
Cabbar F [40] 10 C – Ti Monov G [41] 10 C –
J Oral Maxillofac Surg - 2011 Clin Oral Implants Res - 2005
Yilmaz S [42] 20 C – MGCSH Kutkut A [43] 16 R +/−
J Periodontol - 2011 J Periodontol - 2012
Camargo PM [44] 23 C – Biomaterials
combination
Poeschl PW [45] 14 C +
J Periodontol - 2009 J Oral Maxillofac Surg - 2012
Torres J [46] 87 R + Inchingolo F [47] 127 C +
J Clin Periodontol - 2009 Eur Rev Med Pharmacol Sci - 2012
Dori F [48] 24 R – Kaushick BT [49] 10 R +
J Periodontol - 2007 Indian J Dent Res - 2011
Dori F [50] 30 R – Torres J [51] 30 R +
J Clin Periodontol - 2007 J Clin Periodontol - 2010
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Table 2 Comparative studies on PRP clinical application to favor bone-graft, bone-graft substitutes, or bone implant integration
Publication Results Publication Results
Autologous
bone
Luaces-Rey R [18] Med Oral
Patol Oral Cir Bucal - 2010
Bone increase between the third and sixth months, in
autologous bone alone or in combination with PRP
without any statistical difference
BPBM Camargo PM [13] Int J
Per Rest Dent - 2005
Decrease in pocket depth and an increase in clinical
attachment level and defect filling, with BPBM, GTR,




PRP permitted a 60% reduction in the amount of
bone graft required for normal sinus floor augmentation
and the bone obtained had the same histological
and mechanical properties as the bone obtained
by traditional graft
Lekovic V [17] J Clin
Periodontol - 2003
Greater pocket reduction, an increase in clinical
attachment level, vertical and horizontal defect
filling in the BPBM/GTR/PRP group respect to
open flap debridement
Lee C [24] Int J Oral
Maxillofac Surg - 2009
PRP acceleration of early bone remodelling, but no
significant differences in bone resorption rate between
PRP and particulate cancellous bone and marrow
(PCBM) vs PCBM alone
Camargo PM [19] J
Periodontal Res - 2002
High pocket depth reduction, clinical attachment
gain and defect filling in the PRP/BPBM group
BPBM Anitua E [38] Clin Impl
Dent Rel Res - 2012
More new vital bone than that of the controls in
PRGF-treated samples, and well incorporated bovine
into the new bone formation in the PRGF group
β-TCP Saini N [23] Indian J
Dent Res - 2011
Clinical and radiographic improvement
when PRP was added to β-TCP
Cabbar F [40] J Oral
Maxillofac Surg - 2011
No significant differences in BPBM plus PRP or
alone: bone integration and residual graft particles in
all patients at histological analysis
Ti Monov G [52] Clin Oral
Implants Res - 2005
No statistically significant differences between
titanium plus PRP or titanium alone group
Yilmaz S [42]
J Periodontol - 2011
At 12 months, similar results in probing depth
reduction, attachment gain, clinical and radiographic
bone gain between BPBM plus PPP or plus PRP groups
Biomaterials
combination
Poeschl PW [53] J Oral
Maxillofac Surg - 2012
Significantly better overall graft resorption and
increase in bone formation occurred when PRP
was added to algae-derived HA, Cgraft and
Algipore respect to biomaterials alone
Camargo PM [44] J
Periodontol - 2009
Similar results between BPBM/GTR alone or in
combination with PRP in the decrease of probing
depth, gain in clinical attachment and bone filling
of the defect.
Inchingolo F [54] Eur Rev
Med Pharmacol Sci - 2012
At radiographic point of view presence of newly
formed bone tissue, well amalgamated with the
residual bone in PRP plus autologous bone,
anorganic bone material (Bio-Oss, HA) and organic
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with or without PRP were considered. Those using PRP
in all the treated groups and where other factors were
the only difference were excluded. All papers document-
ing PRP augmentation for orthopaedic procedures were
described separately to understand the evidence available
on its potential in this field.
Results
The literature analysis showed 83 papers on this topic:
26 randomized controlled trials (RCT), 14 comparative
studies, 29 case series, and 14 case reports. The results
showed an increasing interest in this topic over time.
According to the type of material, several implant types
were identified: 24 papers on autologous bone use, 6 on
freeze-dried bone allograft (FDBA), 16 on bovine porous
bone mineral (BPBM), 9 on β-tricalcium phosphate
(β-TCP), 4 on hydroxyapatite (HA), 2 on titanium (Ti), 1
on natural coral, 1 on collagen sponge, 1 on medical-
grade calcium sulphate hemihydrate (MGCSH), 1 on
bioactive glass (BG), and 18 on a combination of bioma-
terials. Only 4 papers were related to the orthopaedic
field, whereas the majority of the results belonged to
clinical applications in oral/maxillofacial surgery.
Autologous bone
Autologous bone represents the gold standard for bone
replacement, because it offers minimal immunological
rejection, complete histocompatibility, provides the best
osteoconductive and osteoinductive properties, and is in-
expensive and easy to obtain [55]. Nevertheless, it also
has some drawbacks, such as donor site morbidity, need
for general anesthesia or sedation, occasional need for
more than one surgical site and limited availability [55].
Several studies have reported its use in combination with
PRP to improve bone implant integration.
In 2005 Raghoebar et al. [30] analysed 30 patients that
underwent floor augmentation of the maxillary sinus
and were randomly assigned to autologous bone graft
and PRP or autologous bone alone. No differences be-
tween treatments were observed, thus showing no add-
itional value of PRP on implant integration. Conversely,
in 2006 Consolo et al. [28] reported the regenerative po-
tential of PRP when used with autologous bone, but this
effect appeared to be restricted to shorter treatment
times: 16 patients underwent bilateral sinus floor aug-
mentation, using autologous bone on one side and PRP
plus autologous bone contralaterally. At 4 months, the
PRP group showed higher bone activities documented
by histological analysis, but a progressive extinguishment
of the PRP effect was recorded after a time of longer
than 6–7 months. In 2008 Schaaf et al. [26] showed no
significant differences in bone volume and implant fail-
ure using autologous bone graft alone or in combinationwith PRP in 34 sinus floor augmentations. In 2010, Badr
et al. [20] used PRP in combination with bone iliac crest
graft in maxilla defects: 22 patients were randomly di-
vided into two groups: PRP augmented and controls. No
significant differences were detected for implant stability
or mean graft resorption and soft tissue healing indices.
Only the posterior implant subgroup showed higher sta-
bility values, although not clinically significant. Finally in
2012, Khairy et al. [12] evaluated the potential benefit of
PRP in conjunction with autologous bone for maxillary
sinus augmentation in 15 patients; autogenous bone
alone was used as the control group. PRP improved the
handling properties of the graft material but did not im-
prove bone density at 3 months. However, PRP-enriched
bone grafts were associated with superior bone density
at 6 months.
Freeze-dried bone allograft
FDBA is derived from the removal of water by the fro-
zen tissue with subsequent vacuum-packing and storing
at room temperature for up to 5 years [3].
Kassolis et al. [36] in 2005 investigated the use of PRP
in combination with FDBA in 10 patients who under-
went bilateral maxillary subantral sinus augmentation.
The subjects were randomly assigned to FDBA plus PRP
or FDBA plus resorbable membrane of polytetrafluoro-
ethylene (e-PTFE). Biopsies were obtained 4.5 to 6 months
after treatment and revealed a significantly higher percent-
age of sinus vital tissue in the PRP group. A lower percent-
age of residual graft particles and a higher rate of bone
formation, although not significant, were detected in the
PRP treatment group. In 2008, Piemontese et al. [34] per-
formed a double-blinded RCT on 60 patients with infrab-
ony osseous defects derived from chronic periodontitis
and treated with FDBA and PRP or FDBA alone. One year
after treatment, both groups showed similar significant
changes in the gingival index, bleeding on probing, prob-
ing depth, clinical attachment level and radiographic pa-
rameters, but a greater probing depth reduction and
clinical attachment gain were seen in the PRP group.
However, with regards to bone regeneration, PRP did not
seem to give any additional value. Similarly, in 2009
Markou et al. [32] compared FDBA plus PRP with FDBA
alone in 24 patients with severe chronic periodontitis. At
six months the two treatment groups were comparable
and the percentage of defect filling did not differ
significantly.
Bovine porous bone mineral
BPBM is a xenograft prepared by protein extraction of
bovine bone, which results in a structure similar to hu-
man cancellous bone and has the ability to enhance
bone formation [56]. The advantages of xenografts in-
clude their relative abundant supply, ease of use, and
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one drawback in its use concerns the possible risk of
disease transmission, such as bacterial, viral, and prion
transmission [57].
The combination of PRP and BPBM has been applied
by many research groups, mainly focusing on periodon-
tal regenerative therapy.
In 2004, Hanna et al. [15] reported their experience in
the treatment of periodontal intrabony defects using
BPBM and PRP: 13 patients were randomly assigned to
BPBM or BPBM plus PRP groups. After 6 months sig-
nificant benefits with both treatments were revealed, but
in the PRP group better results were found in probing
reduction and clinical attachment level. In 2007, Dori
et al. [48] investigated the use of BPBM/GTR alone or in
combination with PRP for the treatment of 24 intrabony
defects related to chronic periodontal disease, and
showed no differences in any of the studied parameters.
Similar results were reported in another RCT performed
by the same author, who in 2007 analysed 30 patients
treated with BPBM/GTR/PRP or BPBM/GTR alone:
PRP did not give any additional value [50]. Conversely, a
good clinical outcome was reported by Torres et al. [46]
two years later: 87 patients underwent sinus floor aug-
mentation with BPBM alone or in combination with
PRP. Histological analysis revealed that bone regener-
ation was significantly higher in sites treated with PRP
and BPBM, whereas graft resorption was similar in both
groups.Ceramics
Ceramics have been widely used for their osteoconduc-
tive properties. Most calcium phosphate ceramics cur-
rently under investigation are synthetic and composed of
HA (Ca10[PO4]6[OH2]), TCP (Ca3[PO4]2), or a combin-
ation of the two [3]. Clinically good short-term results
have been reported for bone grafting with ceramic bone
substitute materials [58].β-Tricalcium phosphate
In 2003, Wiltfang et al. [31] analysed 39 patients under-
going sinus floor elevation with β-TCP alone or in com-
bination with PRP. At 6 months, the formation of new
bone was 8-10% higher when PRP was added, even if it
did not accelerate the degradation of the ceramic bone
substitute. Four years later, Yassibag-Berkman et al. [29]
tested the efficacy of β-TCP alone or in combination
with PRP and GTR in 25 patients: the defects were ran-
domly and equally assigned to three groups, β-TCP
alone, β-TCP with PRP and β-TCP with PRP and GTR.
No statistically significant differences in clinical and
radiographic measurements were observed among the
groups.In 2008, Dori et al. [27] investigated the use of PRP
and β-TCP in subjects with intrabony defects caused by
chronic periodontal disease: 28 patients were randomly
divided into two groups, PRP plus β-TCP and GTR vs β-
TCP plus GTR. No significant differences between the
groups were observed, thus no additional value was pro-
vided by PRP. One year later, Harnack et al. [25] re-
ported the results of an RCT including 22 patients with
intrabony defect caused by periodontitis treated with β-
TCP in combination with PRP or alone. Both groups
showed a similar clinical improvement, thus suggesting
that PRP did not enhance or improve bone healing or β-
TCP integration. More recently, Ozdemir et al. [21]
treated 14 patients with chronic periodontitis (a total of
28 defects) using PRP plus β-TCP or β-TCP alone: no
statistically significant differences between the two groups
in clinical and radiographic values were observed.
Hydroxyapatite
In 2005, Okuda et al. [37] reported promising results
using HA together with PRP: 35 patients were treated
with HA alone or in combination with PRP and they
were evaluated at one year. Significant changes in prob-
ing reduction, clinical attachment gain and vertical rela-
tive attachment gain suggested that PRP may led to
more favourable results compared to HA alone.
More recently in 2011, Vaishnavi et al. [35] showed
good results evaluating 20 subjects randomly assigned to
four treatments: HA, PRP, HA plus PRP, and no substi-
tutes. Radiographic evaluation showed complete bone
regeneration in group I at 1 year, group II at the end of
9 months, group III at the end of 6 months, whereas the
last group showed no satisfactory bone regeneration,
even at the end of one year. This suggests that PRP fa-
vours better and faster bone regeneration combined with
HA. Finally, in 2012 Menezes et al. [33] treated 60 intra-
osseous defects derived from chronic periodontitis with
PRP and HA or a mixture of HA and saline. The 1-year
results showed no significant changes when compared
with baseline; however, the 4-year results indicated that
the test group exhibited a more favourable clinical im-
provement in intraosseous periodontal defects.
Bioactive glass
Among various subgroups of alloplastic bone grafts, BG
is a kind of bioactive ceramic [59] consisting of SiO2,
CaO, Na2O and P2O5. It has been suggested that bio-
active glasses bond to bone without a fibrous connective
tissue interface [60]. Schepers and Ducheyne [60] evalu-
ated bone growth around bioactive glass particles in dog
bone defects in comparison to hydroxylapatite particles,
and reported that narrow-size (300– 355 mm) BG has
an osteostimulatory effect besides its osteoconductive
properties. Moreover, in soft and hard tissue measurements
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alized freeze-dried bone allografts (DFDBA) and BG
grafted sites [61]. In 2007, Demir et al. [39] randomly
treated 29 intra-bony defects with either PRP/BG or BG
alone, and found no additional benefit in the reduction of
pocket depth, clinical attachment gain, and defect filling.
MGCSH
MGCSH is a material that has a long history of clinical
use, thanks to its biocompatibility and rapid and com-
plete resorption, although these properties can some-
times be a drawback in the healing process. MGCSH
can be used as a carrier to deliver GFs. In 2012, Kutkut
et al. [62] reported promising results with PRP and
MGCSH: after extraction of a tooth 16 patients received
a combination of MGCSH/PRP (test group) or collagen
resorbable plug dressing material (control group). The
rate of new vital bone after 3 months of healing was
66.5% in the test group compared to 38.3% in the con-
trol group. Moreover, PRP enhanced rapid bone healing
with respect to PRP-free collagen resorbable graft, but
the difference in the material used in the study group
prevents a true assessment of the role of PRP.
Biomaterial combinations
Biomaterials can also be used in combination to in-
corporate all the favourable material properties in one
implant.
In 2010, Torres et al. [63] investigated the role of PRP
in alveolar ridge augmentation with Ti-mesh and BPBM.
Higher bone augmentation and no Ti-mesh exposure
were seen in the PRP group. One year later, Kaushick
et al. [41] investigated the use of PRP together with HA/
b-TCP: defects of 10 patients were randomly assigned to
test (PRP/HA/b-TCP) or saline-HA/b-TCP. PRP permit-
ted a greater reduction in probing pocket depth, gain in
attachment level and amount of radio density with re-
spect to the control group.
The present analysis suggests that PRP might not be
indicated for b-TCP implants, controversial results are
obtained with autologous bone, whereas a better poten-
tial seems to lie in the augmentation of HA implants. In
particular, only 2 out of 6 papers showed good results
for the integration of β-TCP, 5 out of 10 for autologous
bone, 1 out of 3 for FDBA, 2 out of 11 for BPBM (4 with
less clear evidence of PRP effect), whereas 2 out of 3
papers showed good results for the integration of HA
(the third one showed some benefit but with less clear
evidence).
Orthopaedic papers
Only a few orthopaedic papers were found in the present
search. In 2007, Smrke et al. [43] described the use of allo-
genic PRP in combination with autologous cancellousbone for the treatment of a tibial fracture and delayed
union after insufficient initial osteosynthesis in a 50-year-
old type 2 diabetic man. After 6 months, the graft was in-
corporated, the bone defect was fully bridged and full
weight-bearing capacity was achieved. No side effects and
no signs of platelet or HLA I antibodies were reported. In
the same year, Dallari et al. [51] also showed good results
in 33 patients undergoing high tibial osteotomy to treat
genu varum. Subjects treated with lyophilized bone chips
and PRP, with or without bone marrow stromal cells
showed better osseointegration and faster bone healing. In
2011 Sys et al. [49] assessed both the clinical and radio-
logical effect of PRP with autogenous bone in posterior
lumbar interbody fusion. Forty patients were randomly
treated with autogenous bone alone or in combination
with PRP; the subjects were examined at 3, 6, 12, and
24 months postoperatively. The radiographic outcome
showed uneventful osseous healing in all patients with no
significant differences, but clinical improvement was more
pronounced (even if not significantly) in patients who re-
ceived autografts with PRP. More recently, Wei et al. [45]
investigated the use of the same construct to treat 276 cal-
caneal fractures: the subjects were randomly divided into
3 groups: autogenous bone alone; allograft bone with PRP;
and allograft alone. Results showed that PRP augmented
the favourable outcome of allografts in the management
of displaced calcaneal fractures: at 12 months no signifi-
cant differences were found between 3 groups, but at 24
and 72 months the results of autologous bone and the
allograft with PRP were similar and both were significantly
better than the allograft alone.
Discussion
This systematic research has shown a growing interest
in this biological treatment approach as augmentation
procedure to favour integration of bone-graft, bone-graft
substitutes, or bone implants with bone and soft tissues,
by documenting an increasing number of published
studies over time. However, knowledge on this topic is
still preliminary, as demonstrated by the presence of low
quality studies due to weak methodology, small number
of patients and short-term follow-up.
The orthopaedic and oral/maxillofacial implants sector
forms a significant portion of the biomedical industry
and represents a combined $2.8 billion market [47]. The
clinical need in all of these areas is justified by increasing
prevalence of physically active lifestyles and higher ex-
pectations of quality of life in older age groups as well as
the ageing population affected by problems of bone
healing. Success in the application of an implant de-
pends on many and interconnected factors, that Wang
et al. identified as surgeon, patient, and implant factors
[6]. However, implant failure may be prevented by adding
many coadjuvant agents, which may enhance implant
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tion. Among these, PRP is emerging as a powerful tool for
soft and hard tissue healing, thanks to the GFs contained
in platelet alpha-granules.
The search showed that among RCT and comparative
papers, 16 reported favourable results for PRP augmen-
tation, 18 obtained no significant difference with or
without PRP and 6 underlined the doubtful role of PRP.
The great heterogeneity of clinical outcomes can be
also explained by the different PRP products that have
been used: several different procedures have been de-
scribed to obtain PRP, thus implying qualitative and
quantitative differences among substances (number of
platelets concentrated, leukocyte content,..) [64]. Weibrich
et al. [65] showed in vivo that PRP seems to be able to ac-
tivate the osseous regeneration processes under optimized
conditions, but these are not completely understood and
require further studies. PRP activation is another source
of variability: some authors do not activate platelets,
whereas others use autologous thrombin, calcium chlor-
ide, and even physical methods or biomaterials [7]. Finally,
applicative protocols can vary widely in terms of amount
of substance, number of administrations and timing.
Another controversial point that adds a new variable
to this specific type of application concerns the identifi-
cation of a material that seems to benefit best from PRP
augmentation: the lack of comparison between healing
potential of biomaterials and PRP, differences in study
design and in defects sizes, and low number of patients
studied are the main problems that hamper the drawing
of conclusions.
The present analysis of RCT and comparative studies
showed that a combination of autogenous bone and PRP
led to good results only in 5/10 trials, and only 1 of 3
and 2 of 11 studies reported a good clinical outcomeFigure 2 The literature analysis shows a growing interest on this PRP
is highlighted.using FDBA and BPBM, respectively. A clinical com-
parative trial published in 2008 and performed by
Czuryszkiewicz-Cyrana [16] described a better clinical
outcome when PRP was added to autologous bone com-
pared to the addition to β-TCP, thus confirming the
present literature findings: only 2 of 6 b-TCP trials
found a positive role of PRP during osseointegration.
HA implants seem to be the ideal candidate since good
clinical outcomes were achieved in all the papers de-
scribed and promising results, but less conclusive findings,
have been reported with combinations of biomaterials.
Finally, only one paper was found for both BG and
MGCSH with contrasting results: PRP does not add any
value when used in combination with BG, whereas it
seems to provide positive and faster results with MGCSH.
Summarizing, for most of the documented applica-
tions we do not have enough evidence to draw clear
conclusions on the role of PRP as an augmentation pro-
cedure. Fortunately, the number of high quality studies
are increasing over time, compared to case series and
case reports, as shown in Figure 2, and hopefully in the
near future some of the many still open questions might
be answered. The present analysis suggests that PRP
might not be indicated for b-TCP implants, controversial
results are obtained with autologous bone, whereas a
better potential seems to lie in the augmentation of HA
implants. One aspect to be considered is that, besides
having a good effect or lack of effect, it does not seem
that PRP had a negative effect. However, the weakness of
the literature in this field and preclinical findings of a
potentially deleterious effect [14] suggest caution and
applying PRP as an augmentation procedure only in
controlled studies until more evidence will give us better
indications on the safety and potential of this biological
treatment approach.application. In particular an increasing number of high-quality trials
Roffi et al. BMC Musculoskeletal Disorders 2013, 14:330 Page 9 of 11
http://www.biomedcentral.com/1471-2474/14/330An emerging aspect that could represent a further
possible application modality of this biological treatment
is the potential use of PRP in combination with other
bioactive molecules involved in bone metabolism cas-
cade, as bone morphogenetic proteins (BMPs) [66]. It is
well known that these molecules can induce bone forma-
tion in a variety of indications [67], and recent findings
showed that PRP combined with human recombinant
BMP2 may promote bone formation in bony defects [67].
This seems to be a promising development of PRP use as
augmentation procedure and might provide a fascinating
approach to explore in the near future for the enhance-
ment of osteointegration. However, as for all the various
applications analysed in this systematic review, the real
potential of this blood derivative still needs to be studied
and robust trials are required before an indiscriminate ap-
plication of PRP in the clinical practice.
Conclusions
Systematic research showed a growing interest in this
treatment approach for the integration of bone-graft,
bone-graft substitutes, or bone implants, with an in-
creasing number of published studies over time. How-
ever, knowledge on this topic is still preliminary, and the
few studies available are mainly of low quality.
We do not have enough evidence to draw clear con-
clusions on the role of PRP as an augmentation proced-
ure: among RCT and comparative papers, 16 reported
favourable results, 18 obtained no significant difference
with or without PRP and 6 underlined the doubtful role
of PRP.
With regards to materials type, PRP might not be indi-
cated for b-TCP implants, controversial results are ob-
tained with autologous bone, whereas a better potential
seems to lie in the augmentation of HA implants.
However, several aspects have to be clarified, such as
what biomaterials can benefit the most from PRP and
what is the best protocol for PRP both for production
and application. Randomized controlled trials are needed
to support the potential of this treatment approach and
the advantages and disadvantages of PRP as an augmen-
tation procedure to favour implant integration.
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